Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2012 by Shandong Lanjin Pharmaceuticals Co.,Ltd
Sponsor:
Information provided by (Responsible Party):
Shandong Lanjin Pharmaceuticals Co.,Ltd
ClinicalTrials.gov Identifier:
NCT01570049
First received: March 29, 2012
Last updated: August 1, 2012
Last verified: August 2012

March 29, 2012
August 1, 2012
April 2010
September 2012   (final data collection date for primary outcome measure)
Overall response rate (ORR=CR+PR) of bendamustine hydrochloride in patients who are refractory to rituximab therapy. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Assess the objective response rate (ORR=CR+PR) to a specimen of bendamustine in patients who are refractory to rituximab therapy. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01570049 on ClinicalTrials.gov Archive Site
  • Safety profile of Bendamustine hydrochloride in this patient population [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • Progression free survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Assess safety profile of Bendamustine HCl for injection in this patient population [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • Assess progression free survival(PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Assess overall survival (OS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma
A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma

The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.

This is multicenter, open label study to evaluate the safety and efficacy of bendamustine HCl in patients with indolent Non-hodgkin's lymphoma and relapsed after rituximab treatment. This injection will be given through i.v. infusion in >= 60 minutes on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for up to 8 cycles unless progressive disease or unacceptable toxicity take place. Patients will be followed for up to 1 year before evaluating progression free survival (PFS) and overall survival (OS).

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-Hodgkin Lymphoma by Clinical Course
Drug: Bendamustine
for injection
Experimental: Bendamustine
Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
Intervention: Drug: Bendamustine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 to 75 years
  • B-cell indolent lymphoma proved by biopsy, exclude CLL/SLL
  • Rituximab refractory or relapsed lymphoma patients
  • At least 1 measurable tumor with shortest diameter being of > 1.0cm and longest diameter being of > 1.5cm
  • ECOG PS ≤ 2
  • Anticipated Survival is more than 3 months
  • Hematopoietic function is normal during 14 days before enrollment (unless those abnormities related to lymphoma aggression), including: hemoglobin (Hb) ≥ 8.0g/dl (5.0mmol/L); absolute neutrophil count (ANC) ≥ 1.5X109/L; Platelet count (PLT) ≥ 80X109/L. Acceptable range for abnormities related to lymphoma aggression: Platelet count (PLT) ≥ 50X109/L; White blood cell count (WBC) ≥ 3.5X109/L; Absolute neutrophil count (ANC) ≥ 1.0X109/L
  • Female subjects should not be pregnant and breast-feed, should have contraceptive method during the clinical trial and 12 months thereafter.
  • Subject (or his/her legal representative) agrees to participate the trial and sign the informed consent form

Exclusion Criteria:

  • Those who can not tolerate bendamustine treatment according to investigators view
  • Transferred to high grade malignant lymphoma (from low grade follicular lymphoma)
  • 3b grade follicular lymphoma
  • With central nervous system diseases or medical history (e.g., central nervous system lymphoma or lymphoma related meningitis )
  • With other anticancer treatment during the last 4 weeks
  • Regularly administrated corticosteroid during the last 4 weeks, unless the dose is less or equivalent to 20mg/d prednisone
  • Had tumors or have other tumors, not including non-melanoma skin cancers and cervical carcinoma in situ be treated properly
  • Underwent surgical operation within 28 days before enrollment (exclude lymph node biopsy)
  • Renal disfunction: serum creatinine is more than 1.5 times of upper limit of normal value
  • Hepatic insufficiency: serum total bilirubin is > 1.5 times of upper limit of normal value; AST, ALT is > 2.5 times of upper limit of normal value
  • Known HIV infection or HBV, HCV related active infections; HBsAg is positive; HBcAb is positive and virus copy number is > 1000
  • For patients with other severe medical diseases interfering with their participations of this study(e.g., infections and diabetes not controlled well, gastric ulcer, other lung diseases, active autoimmune diseases), the suitability of participation is judged by investigators
  • Patients participated in other clinical studies and got medical treatments within 30 days prior to enrollment of this trial
  • Other medical and psychological conditions that influence the patients participation or signing of informed consent form
Both
18 Years to 75 Years
No
Contact: Huaqing Wang, Master +86-022-2334-0123
China
 
NCT01570049
RGB-NHL
Yes
Shandong Lanjin Pharmaceuticals Co.,Ltd
Shandong Lanjin Pharmaceuticals Co.,Ltd
Not Provided
Principal Investigator: Huaqing Wang, master Tianjin Medical University Cancer Institute and Hospital
Shandong Lanjin Pharmaceuticals Co.,Ltd
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP